2019
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeOverall survivalHMA cyclesHMA therapyProvider experienceCox proportional hazards modelOlder MDS patientsMedian overall survivalPercent of patientsSEER-Medicare dataMultivariate logistic regressionProportional hazards modelHMA initiationClinical outcomesMDS patientsClinical trialsMedian numberHMA treatmentHazards modelPatientsSignificant associationLogistic regressionPopulation-level survivalSurvivalSyndrome
2012
Medicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: A Medicare-Database Analysis.
Davidoff A, Hendrick F, Stuart B, Zeidan A, Shenolikar R, Gore S, Baer M. Medicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: A Medicare-Database Analysis. Blood 2012, 120: 3176. DOI: 10.1182/blood.v120.21.3176.3176.Peer-Reviewed Original ResearchErythropoiesis stimulating agentsLow-income subsidyPart D claimsMyelodysplastic syndromePart D plansPrior authorizationStudy cohortD claimsOOP paymentsMDS diagnosisPart DUse of ESAsPart D.Lower-risk myelodysplastic syndromesPoor functional statusChronic renal failureD plansErythropoiesis-stimulating agentsMultivariate logistic regressionTreatment of anemiaPart D coverageMedicare Part APlan characteristicsPrescription drug coveragePatient-level observations